Trial Profile

A clinical trial evaluating SPVN 20 in advanced and late-stage Retinitis pigmentosa patients

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 16 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPVN 20 (Primary)
Indications Retinitis pigmentosa
Focus Adverse reactions

Most Recent Events

16 Sep 2022 New trial record
15 Sep 2022 According to a SparingVision media release, RD Fund (Retinal Degeneration Fund) announces its financing for SparingVision.Proceeds from the financing will be used to fund the first, in-human trials of SPVN20.
14 Sep 2022 Accordng to a SparingVision media release, this trial is expected in 2024, with first safety and activity data expected in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com